The manufacturing of recombinant protein is traditionally divided in two main steps:
upstream (cell culture and synthesis of the target protein) and downstream (purification and …

Recombinant therapeutic proteins (RTPs) are important parts of biopharmaceuticals.
Chinese hamster ovary cells (CHO) have become the main cell hosts for the production of …

Glycosylation is one of the structurally diverse and complex forms of post translational
modifications observed in proteins which influence the effector functions of IgG-Fc. Although …

The N-linked glycan profiles on recombinant monoclonal antibody therapeutics significantly
affect antibody biological functions and are largely determined by host cell genotypes and …

The addition of nutrients and accumulation of metabolites in a fed-batch culture of Chinese
hamster ovary (CHO) cells leads to an increase in extracellular osmolality in late stage …

Kinetic models offer incomparable insight on cellular mechanisms controlling protein
glycosylation. However, their ability to reproduce site-specific glycoform distributions …

Chinese hamster ovary (CHO) cells are the most widely used mammalian host cells for the
commercial production of therapeutic proteins. Fed-batch culture is widely used to produce …

In order to meet the rising demand for biologics and become competitive on the develo**
biosimilar market, there is a need for process intensification of biomanufacturing processes …

Glycosylation is a key critical quality attribute for monoclonal antibodies and other
recombinant proteins because of its impact on effector mechanisms and half‐life. In this …

Exerting control over the glycan moieties of antibody therapeutics is highly desirable from a
product safety and batch‐to‐batch consistency perspective. Strategies to improve antibody …